prikaz prve stranice dokumenta Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group
  Preuzmi
PDF 402.57 KB
Znanstveni rad - Izvorni znanstveni rad
Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group
Haematologica, 95 (2010), 9; 1489-1495. https://doi.org/10.3324/haematol.2009.018580
Labar, Boris; Suciu, Stefan; Willemze, Roel; Muus, Petra; Marie, Jean-Pierre; Fillet, Georges; Berneman, Zwi; Jakšić, Branimir; Fereman, Walter; Bron, Dominique; Sinnige, Harm; Mistrik, Martin; Vreugdenhil, Gerard; de Bock, Robrecht; Nemet, Damir; Gilotay, Caroline; Amadori, Sergio; De Witte, Theo Više autora...

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Labar, B., Suciu, S., Willemze, R., Muus, P., Marie, J. P., Fillet, G. ... De Witte, T. (2010). Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group. Haematologica, 95. (9), 1489-1495. doi: 10.3324/haematol.2009.018580

Labar, Boris, et al. "Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group." Haematologica, vol. 95, br. 9, 2010, str. 1489-1495. https://doi.org/10.3324/haematol.2009.018580

Labar, Boris, Stefan Suciu, Roel Willemze, Petra Muus, Jean Pierre Marie, Georges Fillet, Zwi Berneman, et al. "Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group." Haematologica 95, br. 9 (2010): 1489-1495. https://doi.org/10.3324/haematol.2009.018580

Labar, B., et al. (2010) 'Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group', Haematologica, 95(9), str. 1489-1495. doi: 10.3324/haematol.2009.018580

Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, i sur.. Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group. Haematologica [Internet]. 09.2010. [pristupljeno 25.12.2024.];95(9):1489-1495. doi: 10.3324/haematol.2009.018580

B. Labar, et al., "Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group", Haematologica, vol. 95, br. 9, str. 1489-1495, Rujan 2010. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:448295. [Citirano: 25.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:448295
Podaci o radu
Naslov (engleski)Dexamethasone versus prednisolone for adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) patients - final results of the ALL-4 randomized, Phase III trial of the EORTC Leukemia Group
AutorBoris Labar
AutorStefan Suciu
AutorRoel Willemze
AutorPetra Muus
AutorJean-Pierre Marie
AutorGeorges Fillet
AutorZwi Berneman
AutorBranimir Jakšić
AutorWalter Fereman
AutorDominique Bron
AutorHarm Sinnige
AutorMartin Mistrik
AutorGerard Vreugdenhil
AutorRobrecht de Bock
AutorDamir Nemet
AutorCaroline Gilotay
AutorSergio Amadori
AutorTheo De Witte
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Background Corticosteroids are the standard component for the treatment of ALL and LL patients. Our aim was to assess whether dexamethasone (DXM) result in a better outcome than Prednisolone (PDN). Design and Metdhods Adult ALL and LL patients were randomized to receive in induction on days 1-8, 15-22, either DXM 8 mg/m(2) or PDN 60 mg/m(2). Those who reached complete remission (CR), two courses of consolidation (HAM and MA) were administered. Subsequently patient younger than 50 years, with a donor, had to receive AlloSCT, whereas the others, either autoSCT or high dose maintenance chemotherapy with prophylactic CNS irradiation. Randomization was done with a minimization technique. The primary endpoint was event-free survival (EFS). Analysis were done by intention to treat. RESULTS: Between August 1995 and October 2003, 325 patients between 15 to 72 years of age were randomized to receive either DXM (163 patients) or PDN (162 patients). After induction and first consolidation course, 131 (80,4%) patients in DXM group and 124(76,5%) in PDN group achieved CR. No significant difference was observed between the 2 treatment groups regarding EFS: P=0.82, hazard ratio 0.97, 95% confidence interval 0.75-1.25, the 6-year EFS rates (+/-SE) were 25.9%(3.6%) vs. 28.7% (3.5%). Disease-Free survival (DFS) from CR was similar in DXM and PDN group: hazard ratio1.03, 95% confindence interval 0.76-1.40. The 6-year DFS rate was 32.3% (DXM) vs. 37,5% (PDN) group, the 6-year cummulative incidence of relapse was 32.3 (DXM) vs. 37.5% (PDN) group, the 6-year cumulative incidence of relapse was 49.8% vs. 53.5% (Gray test: P=0.30) and of death was 18% vs. 9% (Gray test: P=0.07). Conclusions In the ALL-4 trial in adult patients, DXM did not show any advantage compared to PDN. This study is registered with Clinical Trials gov. number NCT00002700.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHaematologica
Brojčani podacivol. 95, br. 9, str. 1489-1495
p-ISSN0390-6078
DOIhttps://doi.org/10.3324/haematol.2009.018580
URN:NBNurn:nbn:hr:105:448295
Datum objave publikacije2010-09
URL dokumentahttps://doi.org/10.3324/haematol.2009.018580
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 11:36:13